H.C. Wainwright raised the firm’s price target on Niagen Bioscience (NAGE) to $12 from $11 and keeps a Buy rating on the shares. The company’s Q2 revenue and earnings beat expectations, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating
- Niagen Bioscience Reports Strong Q2 Growth and Outlook
- Niagen Bioscience Reports Strong Q2 Sales Growth
- Niagen Bioscience reports Q2 EPS 4c, consensus 1c
- Niagen Bioscience: Promising Clinical Results and Strategic IP Acquisitions Drive Buy Rating